Evermay Wealth Management’s WisdomTree Trust WisdomTree China ex-State-Owned Enterprises Fund CXSE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-32
Closed -$1.11K 551
2022
Q4
$1.11K Hold
32
﹤0.01% 507
2022
Q3
$1K Hold
32
﹤0.01% 492
2022
Q2
$1K Sell
32
-250
-89% -$9.63K ﹤0.01% 490
2022
Q1
$11K Sell
282
-2,112
-88% -$95.4K ﹤0.01% 410
2021
Q4
$119K Hold
2,394
0.02% 215
2021
Q3
$128K Sell
2,394
-16,572
-87% -$953K 0.02% 199
2021
Q2
$1.28M Sell
18,966
-39,603
-68% -$2.59M 0.24% 41
2021
Q1
$3.82M Sell
58,569
-8,326
-12% -$595K 0.76% 14
2020
Q4
$4.4M Buy
66,895
+3,055
+5% +$187K 0.97% 13
2020
Q3
$3.59M Buy
63,840
+610
+1% +$33.1K 0.88% 14
2020
Q2
$3.03M Buy
+63,230
New +$2.71M 0.8% 16

Other funds holding CXSE

Evermay Wealth Management's CXSE Position: Q1 2023 in Review

Evermay Wealth Management sold out of WisdomTree Trust WisdomTree China ex-State-Owned Enterprises Fund (CXSE) in Q1 2023, closing a stake of 32 shares — an estimated $1.11K sold.

Evermay Wealth Management first reported a position in CXSE in Q2 2020 and held it in 11 quarters. The position peaked at $4.4M in Q4 2020. 48 funds tracked by Wall St. Rank hold CXSE as of Q1 2023.

  • Evermay Wealth Management reported no remaining WisdomTree Trust WisdomTree China ex-State-Owned Enterprises Fund position as of Q1 2023 after selling out during the quarter.
  • Evermay Wealth Management sold 32 WisdomTree Trust WisdomTree China ex-State-Owned Enterprises Fund shares in Q1 2023, an estimated $1.11K.
  • Evermay Wealth Management first reported a position in WisdomTree Trust WisdomTree China ex-State-Owned Enterprises Fund in Q2 2020 and held it in 11 quarters.
  • Evermay Wealth Management's WisdomTree Trust WisdomTree China ex-State-Owned Enterprises Fund position peaked at $4.4M in Q4 2020.
  • 48 funds tracked by Wall St. Rank held WisdomTree Trust WisdomTree China ex-State-Owned Enterprises Fund as of Q1 2023.

Based on Evermay Wealth Management's 13F filing for Q1 2023, filed 15 May 2023.